First Manhattan’s Vertex Pharmaceuticals VRTX Stock Holding History

First Manhattan’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$697K	Sell	1,560 -499	-24%	-$233K	﹤0.01%	498
2025 Q4	$933K	Buy	2,059 +479	+30%	+$206K	﹤0.01%	449
2025 Q3	$619K	Sell	1,580 -5	-0.3%	-$2.09K	﹤0.01%	504
2025 Q2	$706K	Buy	1,585 +30	+2%	+$13.8K	﹤0.01%	475
2025 Q1	$754K	Hold	1,555	–	–	﹤0.01%	437
2024 Q4	$626K	Sell	1,555 -15	-1%	-$6.95K	﹤0.01%	465
2024 Q3	$730K	Buy	1,570 +15	+1%	+$7.21K	﹤0.01%	416
2024 Q2	$729K	Buy	1,555 +1	+0.1%	+$434	﹤0.01%	408
2024 Q1	$650K	Buy	1,554 +68	+5%	+$28.7K	﹤0.01%	440
2023 Q4	$605K	Sell	1,486 -74	-5%	-$27.3K	﹤0.01%	444
2023 Q3	$542K	Buy	1,560 +7	+0.5%	+$2.45K	﹤0.01%	469
2023 Q2	$547K	Buy	1,553 +28	+2%	+$9.43K	﹤0.01%	468
2023 Q1	$480K	Sell	1,525 -34	-2%	-$10.2K	﹤0.01%	519
2022 Q4	$450K	Buy	1,559 +9	+0.6%	+$2.74K	﹤0.01%	534
2022 Q3	$448K	Sell	1,550 -200	-11%	-$57.5K	﹤0.01%	527
2022 Q2	$493K	Hold	1,750	–	–	﹤0.01%	545
2022 Q1	$456K	Hold	1,750	–	–	﹤0.01%	598
2021 Q4	$384K	Hold	1,750	–	–	﹤0.01%	616
2021 Q3	$317K	Hold	1,750	–	–	﹤0.01%	651
2021 Q2	$352K	Sell	1,750 -400	-19%	-$83.7K	﹤0.01%	628
2021 Q1	$462K	Sell	2,150 -100	-4%	-$22K	﹤0.01%	554
2020 Q4	$531K	Sell	2,250 -31	-1%	-$7.11K	﹤0.01%	496
2020 Q3	$620K	Sell	2,281 -74	-3%	-$20.4K	﹤0.01%	455
2020 Q2	$683K	Buy	2,355 +25	+1%	+$6.78K	﹤0.01%	444
2020 Q1	$554K	Buy	2,330 +180	+8%	+$41.3K	﹤0.01%	453
2019 Q4	$470K	Buy	2,150 +250	+13%	+$50.6K	﹤0.01%	537
2019 Q3	$321K	Buy	1,900 +1,000	+111%	+$177K	﹤0.01%	606
2019 Q2	$165K	Sell	900 -25	-3%	-$4.37K	﹤0.01%	743
2019 Q1	$170K	Buy	925 +100	+12%	+$18.5K	﹤0.01%	744
2018 Q4	$136K	Hold	825	–	–	﹤0.01%	748
2018 Q3	$159K	Hold	825	–	–	﹤0.01%	764
2018 Q2	$140K	Sell	825 -1,500	-65%	-$233K	﹤0.01%	759
2018 Q1	$378K	Sell	2,325 -140	-6%	-$22.9K	﹤0.01%	572
2017 Q4	$369K	Buy	2,465 +140	+6%	+$20.7K	﹤0.01%	591
2017 Q3	$353K	Hold	2,325	–	–	﹤0.01%	581
2017 Q2	$299K	Hold	2,325	–	–	﹤0.01%	606
2017 Q1	$254K	Hold	2,325	–	–	﹤0.01%	644
2016 Q4	$171K	Sell	2,325 -31	-1%	-$2.52K	﹤0.01%	702
2016 Q3	$205K	Buy	2,356 +1,500	+175%	+$142K	﹤0.01%	663
2016 Q2	$73K	Hold	856	–	–	﹤0.01%	877
2016 Q1	$68K	Hold	856	–	–	﹤0.01%	864
2015 Q4	$107K	Hold	856	–	–	﹤0.01%	801
2015 Q3	$89K	Hold	856	–	–	﹤0.01%	827
2015 Q2	$105K	Buy	856 +31	+4%	+$3.91K	﹤0.01%	816
2015 Q1	$97K	Sell	825 -16	-2%	-$1.92K	﹤0.01%	832
2014 Q4	$99K	Buy	841 +16	+2%	+$1.8K	﹤0.01%	840
2014 Q3	$92K	Hold	825	–	–	﹤0.01%	840
2014 Q2	$78K	Hold	825	–	–	﹤0.01%	863
2014 Q1	$58K	Sell	825 -150,702	-99%	-$11.9M	﹤0.01%	918
2013 Q4	$11.3M	Hold	151,527	–	–	0.07%	159
2013 Q3	$11.5M	Buy	151,527 +115	+0.1%	+$9.15K	0.08%	152
2013 Q2	$12.1M	Buy	+151,412	New	+$11.2M	0.08%	149

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Manhattan's VRTX Position: Q1 2026 in Review

First Manhattan reduced its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, selling an estimated $233K and leaving 1,560 shares worth $697K. The position accounts for ﹤0.01% of the portfolio, ranked #498.

First Manhattan first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.1M in Q2 2013. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

First Manhattan held 1,560 shares of Vertex Pharmaceuticals worth $697K as of Q1 2026.
First Manhattan sold 499 Vertex Pharmaceuticals shares in Q1 2026, an estimated $233K.
Vertex Pharmaceuticals made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #498 holding.
First Manhattan first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
First Manhattan's Vertex Pharmaceuticals position peaked at $12.1M in Q2 2013.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.